These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 8342071

  • 1. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.
    Grochow LB.
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):18-25; quiz 26. PubMed ID: 8342071
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review).
    Vassal G.
    Anticancer Res; 1994 Aug; 14(6A):2363-70. PubMed ID: 7825973
    [Abstract] [Full Text] [Related]

  • 5. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, Choroszy M, Danielson M, Przepiorka D, Chan KW.
    Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, Dupuis LL.
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [Abstract] [Full Text] [Related]

  • 9. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study.
    Bertholle-Bonnet V, Bleyzac N, Galambrun C, Mialou V, Bertrand Y, Souillet G, Aulagner G.
    Ther Drug Monit; 2007 Apr; 29(2):177-84. PubMed ID: 17417071
    [Abstract] [Full Text] [Related]

  • 10. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
    Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van Kesteren C, Bierings M, Rademaker CM, den Hartigh J, Uiterwaal CS, Zwaveling J, Boelens JJ.
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
    [Abstract] [Full Text] [Related]

  • 11. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
    Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL, Wingard JR, Abbott BL, Abhyankar S, McGuirk JP.
    Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
    McPherson ME, Hutcherson D, Olson E, Haight AE, Horan J, Chiang KY.
    Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698
    [Abstract] [Full Text] [Related]

  • 13. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?
    Schuler U, Schroer S, Kühnle A, Blanz J, Mewes K, Kumbier I, Proksch B, Zeller KP, Ehninger G.
    Bone Marrow Transplant; 1994 Nov; 14(5):759-65. PubMed ID: 7889009
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome.
    Chandy M, Balasubramanian P, Ramachandran SV, Mathews V, George B, Dennison D, Krishnamoorthy R, Srivastava A.
    Bone Marrow Transplant; 2005 Nov; 36(10):839-45. PubMed ID: 16151422
    [Abstract] [Full Text] [Related]

  • 15. Chronopharmacology of high-dose busulfan in children.
    Vassal G, Challine D, Koscielny S, Hartmann O, Deroussent A, Boland I, Valteau-Couanet D, Lemerle J, Lévi F, Gouyette A.
    Cancer Res; 1993 Apr 01; 53(7):1534-7. PubMed ID: 8453619
    [Abstract] [Full Text] [Related]

  • 16. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M, Ljungman P, Ringdén O, Hassan Z, Oberg G, Nilsson C, Békassy A, Bielenstein M, Abdel-Rehim M, Georén S, Astner L.
    Bone Marrow Transplant; 2000 May 01; 25(9):915-24. PubMed ID: 10800057
    [Abstract] [Full Text] [Related]

  • 17. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
    Lee JH, Choi SJ, Lee JH, Kim SE, Park CJ, Chi HS, Lee MS, Lee JS, Kim WK, Lee KH.
    Ann Hematol; 2005 May 01; 84(5):321-30. PubMed ID: 15580502
    [Abstract] [Full Text] [Related]

  • 18. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.
    Clopés A, Sureda A, Sierra J, Queraltó JM, Broto A, Farré R, Moreno E, Brunet S, Martino R, Mangues MA.
    Eur J Haematol; 2006 Jul 01; 77(1):1-6. PubMed ID: 16573745
    [Abstract] [Full Text] [Related]

  • 19. Retrospective appraisal of busulfan dose adjustment in children.
    Dupuis LL, Najdova M, Saunders EF.
    Bone Marrow Transplant; 2000 Dec 01; 26(11):1143-7. PubMed ID: 11149723
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
    Kletzel M, Jacobsohn D, Duerst R.
    Biol Blood Marrow Transplant; 2006 Apr 01; 12(4):472-9. PubMed ID: 16545731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.